SCYNEXIS, Inc (SCYX)

JERSEY CITY, N.J., May 20, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Marco Taglietti, President and Chief Executive Officer of SCYNEXIS, will present in person at the upcoming H.C. Wainwright Global Investment Conference, being held May 23-26, 2022, in Miami and virtually. SCYNEXIS Presentation details: H.C. Wainwright Global Investm

Gainers Adaptimmune Therapeutics (NASDAQ:ADAP) stock rose 12.7% to $1.6 during Monday's after-market session. The market value of ...

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus BridgeBio Inks Licensing ...

Scynexis (SCYX) delivered earnings and revenue surprises of 31.08% and 1.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

SCYNEXIS (NASDAQ:SCYX) reported its Q1 earnings results on Thursday, May 12, 2022 at 07:00 AM. Here's what investors ...

BREXAFEMME® (ibrexafungerp tablets), launched in September 2021 for the treatment of vulvovaginal candidiasis (VVC), achieved almost 4,000 prescriptions with net revenues of $0.7 million in Q1 2022. Expansion of the labeling to include prevention of recurrent VVC is anticipated by end of 2022.As of May 2022, BREXAFEMME was covered by commercial insurance plans representing 93 million, or 55% of commercially insured lives.SCYNEXIS initiated MARIO, a global Phase 3 study to evaluate ibrexafungerp

Companies Reporting Before The Bell • Chicago Atlantic Real (NASDAQ:REFI) is projected to report earnings for its ...

SCYNEXIS (NASDAQ:SCYX) is set to give its latest quarterly earnings report on Thursday, 2022-05-12. Here's what investors need to know ...

Data show that of the FURI study patients with refractory or relapsed vulvovaginal candidiasis (VVC) treated with ibrexafungerp, 71.4% had successful clinical outcomes. Ibrexafungerp demonstrated positive results in difficult-to-treat VVC patients with severe fungal infections who were either intolerant to standard antifungal therapy or experienced refractory infections despite treatment.In the study, ibrexafungerp was generally safe and well-tolerated with findings consistent with the existing

JERSEY CITY, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, May 12, 2022 to provide a corporate update and discuss the Company’s financial results for the first quarter ended March 31, 2022. Conference call and webcast details: Investors (domestic): (877

Product theater presentation will be held on May 7 to highlight clinical data and attributes of the first new antifungal class approved in more than 25 yearsJERSEY CITY, N.J., May 04, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, will present new data from its ongoing FURI study of ibrexafungerp during the American College of Obstetricians and Gynecologists

Potential SCYNEXIS, Inc. ( NASDAQ:SCYX ) shareholders may wish to note that the CEO, President & Director, Marco...

The directors of a company tend to have a unique inside view into the business, so when directors make major buys, investors are wise to take notice. Presumably the only reason a director of a company would choose to take their hard-earned cash and use it to buy stock in the open market, is that they expect to make money — maybe they find the stock very undervalued, or maybe they see exciting progress within the company, or maybe both..

A company's own top management tend to have the best inside view into the business, so when company officers make major buys, investors are wise to take notice. Presumably the only reason an insider would take their hard-earned cash and use it to buy stock of their company in the open market, is that they expect to make money — maybe they find the stock very undervalued, or maybe they see exciting progress within the company, or maybe both..

New interim analysis of the Phase 3 CARES study showed complete or partial response in 78% of the 18 patients treated with ibrexafungerp for infections caused by Candida auris, a potentially deadly and multidrug-resistent pathogen with an outbreak recently reported at a Detroit specialty hospital.1 Interim data of the ongoing Phase 3 FURI and CARES studies of patients with invasive candidiasis and candidemia treated with ibrexafungerp is positive and consistent with previous analyses. Additional

JERSEY CITY, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) today announced the closing of its previously announced underwritten public offering of common stock, pre-funded warrants and warrants. The shares and warrants were sold at a public offering price of $3.00 per share and accompanying warrants, and the pre-funded warrants were sold at a public offering price of $2.999 per pre-funded warrant and accompanying warrants. The total gross offering proceeds to SCYNEXIS fr

Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares jumped 100.9% to close at $2.27 on Friday. Vallon Pharmaceuticals ...

SCYNEXIS Inc(NASDAQ: SCYX) hasannounced interim datafrom its ongoing Phase 3 FURI and CARES studies of ...

U.S. stocks extended losses toward the end of trading, with the Dow Jones dropping more than 800 points on Friday. The Dow traded ...

U.S. stocks extended losses midway through trading, with the Nasdaq Composite dropping 200 points on Friday. The Dow traded down ...

U.S. stocks traded lower this morning, with the Dow Jones dropping more than 400 points on Friday. Following the market opening ...

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus WHO Backs Pfizer's Oral ...

Gainers Vallon Pharmaceuticals (NASDAQ:VLON) shares moved upwards by 94.7% to $2.2 during Friday's pre-market session. The company's ...

JERSEY CITY, N.J., April 22, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) today announced the pricing of its underwritten public offering of common stock, pre-funded warrants and warrants. The shares and warrants are being sold at a public offering price of $3.00 per share and accompanying warrants, and the pre-funded warrants are being sold at a public offering price of $2.999 per pre-funded warrant and accompanying warrants. The gross offering proceeds to SCYNEXIS from this offering

Data reinforce findings from previous analyses demonstrating oral ibrexafungerp’s potential to combat difficult-to-treat and refractory fungal infections in the hospital setting.Ongoing FURI and CARES studies are a key component of the SCYNEXIS strategy to build ibrexafungerp into a broad antifungal franchise.SCYNEXIS is presenting the fourth interim analysis from FURI and the second interim analysis from CARES during the 32nd European Congress of Clinical Microbiology and Infectious Diseases (E

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Traders ready for another busy day of investing will want to know all about the biggest pre-market stock movers for Friday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

Gainers Moving iMage Technologies, Inc. (NASDAQ: MITQ) rose 41.7% to $1.63 in pre-market trading. Moving iMage Technologies and ...

Gainers Pyxis Oncology (NASDAQ:PYXS) stock moved upwards by 14.0% to $3.02 during Thursday's after-market session. Pyxis Oncology's ...

SCYNEXIS Inc (NASDAQ: SCYX) shares are trading lower after the company announced a public offering of common stock. The size of the ...

JERSEY CITY, N.J., April 21, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) today announced that it has commenced an underwritten public offering of shares of its common stock and warrants to purchase shares of its common stock, including pre-funded warrants to purchase common stock in lieu of common stock for certain purchasers. SCYNEXIS intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of its common stock and warrants offered